Modern Principles in the Diagnostics and Treatment of Arterial Hypertension;Suvremena Načela u Dijagnostici i Liječenju Arterijske Hipertenzije

Medicus

Volumn 12, Issue 1, 2003, Pages 17-29

  Jelaković, Bojan ^a   Željković, Tajana ^a   Laganović, Mario ^a   Kuzmanić, Duško ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Arterial hypertension; Blood pressure; Diagnosis; Epidemiology; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; NANDROLONE CYCLOHEXYLPROPIONATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT;

BLOOD PRESSURE REGULATION; CALCULATION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; EPIDEMIOLOGICAL DATA; EUROPE; GENERAL PRACTICE; HUMAN; HYPERTENSION; LIFESTYLE; MORBIDITY; REVIEW; RISK ASSESSMENT;

EID: 1842431686     PISSN: 1330013X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. FUENTES R, ILMANIEMI N, LAURIKAINEN E, TUOMILEHTO J, NISSINEN A. Hypertension in developing economies: a review of population based studies carried out from 1980 to 1998. J Hypertens 2000; 18: 521-9.
2. MacMAHON S, PETO R, CUTLER J et al. Blood pressure, stroke and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
3. CHOBANIAN A, BAKRIS G, BLACK H et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. J Am Med Assocc 2003; 289: 3560-72.
4. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
5. WOLF-MAIER K, COOPER R, BANEGAS J et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. J Am Med Assoc 2003; 289: 2363-9.
6. JELAKOVIĆ B. Prikaz epidemioloških podataka o hipertenziji u Hrvatskoj. Usmeno priopćenje. Simpozij Suvremeno liječenje arterijske hipertenzije, Brijuni 6-8. 9. 2002.
7. COLLINS R, MacMAHON S. Blood pressure antihypertensive treatment and risks of coronary heart disease. Br Med Bull 1994; 50: 272-98.
8. ZANCHETTI A, HANSSON L, MENARD J et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study for the HOT Study Group. J Hypertens 2001; 19: 819-25.
9. ROSE G. Epidemiology. U: Marshall A, Barritt D. (ur) The hypertensive patient. Kent, UK: Pitman Medical, 1980: 121.
10. VASAN R, LARSON M, LEIP E et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-927.
11. ANDERSON K, WILSON P, ODELL P, KANNEL W. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-62.
12. CONORY R, PYORALA K, Fitzgerald on the behalf of the SCORE project group. Prediction of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J, 2003. (u tisku).
13. RIDJKE P, BURING J, COOK N, RIFAI N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003; 107: 391-7.
14. JELAKOVIĆ B, LAGANOVIĆ M. Mjerenje arterijskog tlaka - više od tehnike. Liječ Vjesn 2000; 122: 183-6.
15. REIMS H, KJELDSEN S, MANCIA G. Home Blood Pressure Monitoring. ESH Scientific Newsletter: Update on hypertension management. 2002; 3: No12.
16. JELAKOVIĆ B, LAGANOVIĆ M, KUZMANIĆ D. Refraktorna arterijska hipertenzija - u čemu je tvrdokornost? Hic Rhodus, hic salta! Liječ Vjesn 2001; 123: 184-90.
17. JELAKOVIĆ B. Hipertenzivna kriza - pristup bolesniku i liječenje. Liječničke Novine 2003; 17: 24-9.
18. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
19. PERERA G. Hypertensive vascular disease. J Chron Dis 1955; 1: 33-42.
20. 1999 WHO/ISH Hypertension Guidelines-highlights & ESH update. ESH Scientific Newsletter: Update on hypertension management. 2001; 2: No 9.
21. HOLZGRAVE H. Die Kooperation des Patienten bei der Hochdruckentherapie. Muench Med Wschr 1980; 122 (8): 267-70.
22. BLOOM B. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Therap. 1998; 20: 1-11.
23. HYMAN D, PAVLIK V. Self-reported hypertension treatment practices among primary care physicians. Arch Intern Med 2000; 160: 2281-6.
24. SACKS F, SVETKEY L, VOLLMER W et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3-10.
25. Writing Group of PREMIER Collaborative Research Group. Effects of Comprehensive Lifestyle Modification on Blood Pressure Control. Main Resulty of the PREMIER Clinical Trial. J Am Med Assoc 2003; 289: 2083-93.
26. KUZMANIĆ D. Kako odabrati optimalan antihipertenzivni lijek. Medicus 2003; 12 (1): 31-41
27. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium chanel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002; 288: 2981-91.
28. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
29. SEVER P, DAHLOFF B, POULTER N et al. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with awarage or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 2003; 361: 1149-58.
30. DAHLOF B, DEVEREUX R, KSELDESEN et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
31. PEPINE C. International Verapamil SR and Trandolapril Study. Report at the ACC 53 Annual Scientific Session, 2003, April, Chicago USA.